加载中
MoonLake Immunotherapeutics operates as a clinical-stage biopharmaceutical company, concentrating its efforts on discovering and developing novel therapies. The company's primary focus is the advancement of Sonelokimab, an innovative, investigational Nanobody-based treatment engineered to target inflammatory conditions. Currently, Sonelokimab is undergoing mid-stage (Phase II) clinical trials for a range of inflammatory diseases, including hidradenitis suppurativa, psoriatic arthritis, and both ankylosing spondylitis and radiographic axial spondyloarthritis. Established in 2021, MoonLake Immunotherapeutics is based in Zug, Switzerland.
收盘时
US$10.41
−US$0.27 · -2.53%
盘后
US$10.56
+US$0.15 · +1.44%
10月13日 16:47 ET
盘中时间采用ET。市场数据可能有所延迟。
MoonLake Immunotherapeutics operates as a clinical-stage biopharmaceutical company, concentrating its efforts on discovering and developing novel therapies. The company's primary focus is the advancement of Sonelokimab, an innovative, investigational Nanobody-based treatment engineered to target inflammatory conditions. Currently, Sonelokimab is undergoing mid-stage (Phase II) clinical trials for a range of inflammatory diseases, including hidradenitis suppurativa, psoriatic arthritis, and both ankylosing spondylitis and radiographic axial spondyloarthritis. Established in 2021, MoonLake Immunotherapeutics is based in Zug, Switzerland.
日内区间
当前US$10.41
52周区间
当前US$10.41
盘中时间采用ET。市场数据可能有所延迟。
MoonLake Immunotherapeutics operates as a clinical-stage biopharmaceutical company, concentrating its efforts on discovering and developing novel therapies. The company's primary focus is the advancement of Sonelokimab, an innovative, investigational Nanobody-based treatment engineered to target inflammatory conditions. Currently, Sonelokimab is undergoing mid-stage (Phase II) clinical trials for a range of inflammatory diseases, including hidradenitis suppurativa, psoriatic arthritis, and both ankylosing spondylitis and radiographic axial spondyloarthritis. Established in 2021, MoonLake Immunotherapeutics is based in Zug, Switzerland.
日内区间
当前US$10.41
52周区间
当前US$10.41
营业利润
净利润
| 项目（USD） | 2025财年 | 2024财年 | 2023财年 | 2022财年 | 2021财年 |
|---|---|---|---|---|---|
| 销货成本 | 261.6万 USD | — | — | — | 4971 USD |
| 毛利 | −261.6万 USD | — | — | — | −4971 USD |
| 研究与开发 | 2.03亿 USD | 1.13亿 USD | 3180.19万 USD | 4204.9万 USD | 3552.44万 USD |
| 销售、一般及管理费用 | 4197.2万 USD | 3031.98万 USD | 2232.12万 USD | 2301.25万 USD | 1804.77万 USD |
| 营业费用 | 2.42亿 USD | 1.43亿 USD | 5412.31万 USD | 6506.14万 USD | 5357.2万 USD |
| 利息支出 | 724.8万 USD | — | — | — | — |
| 折旧和摊销 | 261.6万 USD | 138.47万 USD | 37万 USD | 16.48万 USD | 4971 USD |
| 营业利润 | −2.45亿 USD | −1.43亿 USD | −5412.31万 USD | −6506.14万 USD | −5357.7万 USD |
| 净利润 | −2.27亿 USD | −1.19亿 USD | −3600.73万 USD | −4997.32万 USD | −5364.36万 USD |
公司数据更新于 2026年10月13日。
已公布业绩及可用的市场共识预期。
已公布业绩及可用的市场共识预期。
第三方分析师预期可能变化，并非 GoAI 建议。
报告持有此股票敞口的交易所交易基金。
T. Rowe Capital Appreciation Equity ETFTCAF261.19万0.03%91.19亿 USD0.31%US$43.55-0.02%
Vanguard Health Care ETFVHT203.37万0.01%220亿 USD0.09%US$316.37-1.34%
iShares ESG Aware MSCI USA Small-Cap ETFESML92.41万0.03%27.28亿 USD0.17%US$52.45-0.02%
T. Rowe Price Exchange-Traded Funds, Inc. - T. Rowe Price Health Care ETFTMED46.74万1.42%3277.95万 USD0.44%US$33.0069-1.87%
Nuveen ESG Small-Cap ETFNUSC45.76万0.04%12.53亿 USD0.31%US$49.21+0.10%
State Street SPDR S&P International Small Cap ETFGWX40.93万0.04%9.15亿 USD0.40%US$45.30+0.09%
Optimize Strategy Index ETFOPTZ34.34万0.13%2.67亿 USD0.25%US$45.3695-0.15%
Fidelity Nasdaq Composite Index ETFONEQ33万—109.4亿 USD0.21%US$107.2-0.15%T. Rowe Capital Appreciation Equity ETFTCAFVanguard Health Care ETFVHTiShares ESG Aware MSCI USA Small-Cap ETFESMLT. Rowe Price Exchange-Traded Funds, Inc. - T. Rowe Price Health Care ETFTMEDNuveen ESG Small-Cap ETFNUSCState Street SPDR S&P International Small Cap ETFGWXOptimize Strategy Index ETFOPTZFidelity Nasdaq Composite Index ETFONEQAI 生成内容及延迟市场数据仅供信息与教育用途，不构成投资建议。
